No Survival Benefit With Extended Lymphadenectomy in Muscle-Invasive Bladder Cancer
(MedPage Today) -- SAN ANTONIO -- Extended compared with standard lymphadenectomy at the time of radical cystectomy provided no survival benefit to patients with muscle-invasive bladder cancer (MIBC), according to a phase III trial.
With a median... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 6, 2024 Category: Hematology Source Type: news
No PSA Recurrence at 24 Months With Apalutamide Plus ADT After Radical Prostatectomy
(MedPage Today) -- SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen deprivation therapy (ADT)... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 5, 2024 Category: Hematology Source Type: news
High Response Rates With Gene Therapies for BCG-Unresponsive Bladder Cancer
(MedPage Today) -- SAN ANTONIO -- More than 70% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) achieved complete responses to a novel gene therapy, a small preliminary trial showed.
Across a range of doses, 16 of... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 5, 2024 Category: Hematology Source Type: news
HIFU Non-Inferior to Prostatectomy for Localized Prostate Cancer
(MedPage Today) -- SAN ANTONIO -- A comparison of high-intensity focused ultrasound (HIFU) and radical prostatectomy (RP) found that HIFU was non-inferior to surgery as primary treatment for localized prostate cancer, according to a French trial... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 4, 2024 Category: Hematology Source Type: news
Active Surveillance Lawsuits; More Eligibility for Studies; Biosimilars Make News
(MedPage Today) -- A study of malpractice lawsuits related to active surveillance for prostate cancer found "no evidence of successful malpractice litigation," leading the authors to conclude that active surveillance "represents a sound management... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 3, 2024 Category: Hematology Source Type: news
Impact of Recombinant Replacement Therapy Detailed in Genetic Clotting Disorder
(MedPage Today) -- A recombinant replacement for the ADAMTS13 protein (Adzynma) missing in congenital thrombotic thrombocytopenic purpura (TTP) restored levels and reduced acute TTP events, according to interim trial data that led to FDA approval... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 1, 2024 Category: Hematology Source Type: news
Glecirasib Shows Promising Efficacy in KRAS-Mutated NSCLC
(MedPage Today) -- Glecirasib, a highly selective covalent oral inhibitor of KRAS G12C, demonstrated promising efficacy in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to a phase II trial from... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 1, 2024 Category: Hematology Source Type: news
Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management
(MedPage Today) -- The history of primary myelofibrosis dates back to 1951 and the description of four distinct clinicopathologic entities that came to be known as myeloproliferative neoplasms (MPNs): chronic myeloid leukemia (CML), polycythemia... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 1, 2024 Category: Hematology Source Type: news
Myelofibrosis: A Rare Malignancy Attracting More and More Attention
(MedPage Today) -- Myelofibrosis remains a rare disease, even though recent attention to the condition might suggest otherwise.
Annual incidence rates for 2000 to 2012 ranged from 0.1 to 1.0 per 100,000. Prevalence has been difficult to measure... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 1, 2024 Category: Hematology Source Type: news
Myelofibrosis: More Than Meets the Eye?
(MedPage Today) -- Myelofibrosis remains a rare disease, even though recent attention to the condition might suggest otherwise.
Annual incidence rates for 2000 to 2012 ranged from 0.1 to 1.0 per 100,000. Prevalence has been difficult to measure... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 1, 2024 Category: Hematology Source Type: news
FDA Approves First Drug for WHIM Syndrome
(MedPage Today) -- The FDA approved mavorixafor (Xolremdi) capsules as the first therapy specifically for WHIM syndrome, a rare primary immunodeficiency and chronic neutropenic disorder, X4 Pharmaceuticals announced on Monday.
Caused by CXC chemokine... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 29, 2024 Category: Hematology Source Type: news
Clue to Aspirin, Colon Cancer Link; New Lutathera Approval; AI & Electronic Records
(MedPage Today) -- Possibly uncovering a clue to a longstanding mystery, Italian researchers found that aspirin may help prevent colorectal cancer by pointing the immune system toward cancer cells. (Cancer)
The FDA expanded indications for lutetium... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 26, 2024 Category: Hematology Source Type: news
Quadruplet Shows 'Excellent Activity' in Myeloma Patients Who Defer HSCT
(MedPage Today) -- Adding the CD38 monoclonal antibody isatuximab (Sarclisa) to a backbone of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) induced deep and durable responses in a multiple myeloma study of untreated transplant... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 26, 2024 Category: Hematology Source Type: news
High Deep-Remission Rate With Triple Regimen for Relapsed/Refractory CLL
(MedPage Today) -- Time-limited treatment with a three-drug combination for relapsed/refractory chronic lymphocytic leukemia (CLL) produced long-term undetectable residual disease in more than 90% of patients, updated results from a prospective... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 25, 2024 Category: Hematology Source Type: news
CAR-T Plus Stem-Cell Transplant Promising for CD7+ Blood Cancers
(MedPage Today) -- A strategy of sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and haploidentical hematopoietic stem-cell transplantation (HSCT), without graft-versus-host disease (GVHD) prophylaxis, is a feasible approach for patients... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 24, 2024 Category: Hematology Source Type: news
